HbA1c test blood collection is a routine, minimally invasive procedure that underpins diabetes diagnosis and long-term glycaemic monitoring across the NHS. The HbA1c test — formally the glycated haemoglobin test — measures average blood glucose levels over the preceding two to three months by detecting the proportion of haemoglobin bonded to glucose. Understanding how blood is collected, what the results mean, and which factors can affect accuracy helps patients prepare confidently and engage meaningfully with their diabetes care. This guide covers everything you need to know, from venepuncture technique and sample handling to interpreting your NHS results.

What Is an HbA1c Test and Why Is It Used?

The HbA1c test measures average blood glucose over two to three months by detecting glycated haemoglobin; it is used to diagnose type 2 diabetes (≥48 mmol/mol) and monitor long-term glycaemic control in people already living with diabetes.

The HbA1c test — formally known as the glycated haemoglobin test — is a blood test that measures the average level of blood glucose (sugar) over the preceding two to three months. It works by detecting the proportion of haemoglobin, the oxygen-carrying protein in red blood cells, that has become chemically bonded to glucose through a process called glycation. Because red blood cells have a lifespan of approximately 90 to 120 days, the HbA1c result reflects sustained glucose exposure rather than a single point-in-time reading.

In clinical practice, the HbA1c test serves two primary purposes. First, it is used to diagnose type 2 diabetes and non-diabetic hyperglycaemia (prediabetes) in eligible adults, in line with NICE guideline NG28 and the WHO 2011 diagnostic statement. A venous laboratory HbA1c result of 48 mmol/mol (6.5%) or above is generally diagnostic of type 2 diabetes. In asymptomatic adults, a second confirmatory test is required; in adults with clear symptoms of diabetes, a single result may be sufficient. A result between 42 and 47 mmol/mol (6.0–6.4%) indicates non-diabetic hyperglycaemia — an increased risk of developing type 2 diabetes. Second, for people already living with diabetes, the test is used to monitor long-term glycaemic control and guide treatment decisions.

Important diagnostic exclusions: HbA1c should not be used to diagnose diabetes in the following groups, where alternative testing pathways apply:

• Children and young people

• Pregnant women or those who have recently given birth (an oral glucose tolerance test (OGTT)-based pathway is used instead — see NICE NG3)

• Adults with suspected type 1 diabetes or acute-onset hyperglycaemia

• Individuals with conditions affecting red blood cell turnover or haemoglobin structure (e.g., haemolytic anaemia, haemoglobinopathies)

In these situations, a fasting plasma glucose, random plasma glucose, or OGTT should be used as appropriate, and urgent clinical assessment sought where type 1 diabetes or a hyperglycaemic emergency is suspected.

The test is widely available through NHS GP surgeries, hospital outpatient departments, and some community clinics. Unlike a fasting plasma glucose test, the HbA1c test does not typically require the patient to fast beforehand, making it more convenient and accessible. It is a cornerstone of diabetes care in the UK and is recommended by both NICE (NG28) and the WHO as a reliable diagnostic and monitoring tool.

How Blood Is Collected for an HbA1c Blood Test

Blood is drawn from a vein — usually in the antecubital fossa — into a purple-topped EDTA tube; for diagnostic purposes, a venous laboratory sample is required, as point-of-care fingerprick devices are not approved for diagnosis.

HbA1c blood collection is a straightforward procedure that can be performed in a GP surgery, NHS phlebotomy clinic, or hospital setting. The test requires only a small volume of blood — typically between 2 and 4 millilitres — which is drawn from a vein, most commonly in the antecubital fossa (the inner crease of the elbow). In some settings, particularly for children or for point-of-care testing, a fingerprick capillary blood sample may be used instead.

The standard venepuncture process involves the following steps:

• A trained phlebotomist or healthcare professional cleans the skin with an antiseptic wipe

• A tourniquet is applied to the upper arm to make the vein more prominent

• A sterile needle is inserted into the vein and blood is drawn into a collection tube

• The tourniquet is released, the needle is withdrawn, and gentle pressure is applied to the site

For HbA1c testing, blood is typically collected into a purple- or lavender-topped EDTA tube, which contains an anticoagulant to prevent clotting and preserve the sample's integrity. The tube is labelled with the patient's details immediately after collection to ensure accurate identification.

Point-of-care HbA1c analysers — devices that can process a fingerprick sample within minutes — are increasingly used in GP surgeries and diabetes clinics. These devices are UKCA/CE-marked and used in NHS settings under quality governance frameworks, including internal quality control (IQC) and external quality assessment (EQA) through schemes such as UK NEQAS for HbA1c. They can provide results during the same appointment, supporting faster clinical decision-making in a monitoring context.

However, for diagnostic purposes, a venous blood sample analysed in an accredited laboratory to IFCC standards is required. Point-of-care HbA1c testing should not be used to diagnose diabetes; this is in line with NICE NG28 and guidance from the Association for Clinical Biochemistry and Laboratory Medicine (ACB) and the Royal College of Pathologists (RCPath).

Preparing for Your HbA1c Blood Test

No fasting is required before a standard HbA1c test; patients should stay well hydrated, wear loose clothing, and inform the phlebotomist of any anticoagulant use or history of difficult venous access.

One of the practical advantages of the HbA1c test is that, in most circumstances, no fasting is required. Unlike a fasting glucose or fasting lipid test, you can eat and drink normally before your appointment. This makes it easier to schedule the test at any time of day without disrupting your routine.

However, there are a few general preparations that can help ensure a smooth and accurate blood collection experience:

• Stay well hydrated in the hours before your test, as adequate hydration makes veins easier to locate and access

• Wear loose-fitting clothing or a short-sleeved top to allow easy access to the arm

• Inform the healthcare professional of any medications you are taking, particularly if you are on anticoagulants such as warfarin, as this may affect post-collection care

• Let the phlebotomist know if you have a history of fainting during blood tests, needle phobia, or difficult venous access

If you are attending for a combined blood test appointment — for example, where HbA1c is being tested alongside a fasting cholesterol or glucose test — you may be asked to fast for a specified period. Always follow the specific instructions provided by your GP surgery or clinic when booking.

For people with diabetes who are monitoring their condition, HbA1c tests are typically performed every three to six months. Once blood glucose is stable and treatment targets are being met, NICE guideline NG28 recommends testing at six-monthly intervals. More frequent testing may be appropriate if treatment has recently changed or if control is suboptimal. Keeping a record of your results over time can be a helpful way to track your progress and discuss any concerns with your healthcare team.

Important: If you are pregnant, HbA1c is not used to diagnose gestational diabetes — your maternity team will arrange appropriate testing (usually an OGTT). If you experience symptoms such as excessive thirst, frequent urination, unexplained weight loss, or extreme fatigue, contact your GP promptly rather than waiting for a routine test. If you feel acutely unwell with these symptoms, seek same-day urgent medical attention, as these may indicate type 1 diabetes or a hyperglycaemic emergency requiring immediate assessment.

What Happens to Your Sample After Collection

The EDTA sample is analysed by HPLC or immunoassay in an accredited laboratory aligned to IFCC standards, with routine results typically returned to the requesting clinician within 24 to 72 hours.

Once your blood sample has been collected, it is labelled and transported to a laboratory — either within the same healthcare facility or at an external NHS or accredited private laboratory. Proper handling of the sample during this stage is essential to ensure accurate results.

In the laboratory, the EDTA blood tube is processed using high-performance liquid chromatography (HPLC) or immunoassay techniques, both of which are internationally standardised methods for measuring HbA1c. These methods are aligned with the International Federation of Clinical Chemistry (IFCC) reference system, which underpins the mmol/mol reporting units used in the UK. The NHS transitioned from percentage-based reporting (NGSP/DCCT units) to IFCC mmol/mol units in 2011 to improve consistency across laboratories. Laboratories participate in external quality assessment through UK NEQAS for HbA1c to ensure ongoing accuracy and comparability of results.

Sample stability is an important consideration. EDTA-preserved blood samples for HbA1c are generally stable for several days at room temperature and for longer periods if refrigerated, though exact stability limits depend on the analyser and local laboratory policy. Samples collected in community settings and transported to centralised laboratories remain reliable provided they are handled in accordance with the relevant laboratory's sample handbook.

Results are typically returned to the requesting clinician within 24 to 72 hours for routine laboratory tests, though turnaround times vary by provider and test priority; point-of-care devices can produce results within minutes. Your GP or diabetes nurse will then review the result in the context of your overall clinical picture before contacting you — usually via letter, online patient portal (such as the NHS App), or telephone. If your result indicates a significant change or requires urgent action, your surgery should contact you promptly. If you have not received your results within the expected timeframe, it is reasonable to contact your GP surgery directly.

Understanding Your HbA1c Results on the NHS

UK results are reported in mmol/mol: below 42 is normal, 42–47 indicates non-diabetic hyperglycaemia, and 48 or above is indicative of type 2 diabetes, with a second confirmatory test required in asymptomatic adults.

HbA1c results in the UK are reported in millimoles per mole (mmol/mol), in line with IFCC standardisation. Understanding what your result means is an important part of managing your health. The NHS and NICE use the following reference ranges for adults:

• Below 42 mmol/mol: Normal — no indication of diabetes or prediabetes

• 42 to 47 mmol/mol: Non-diabetic hyperglycaemia (prediabetes) — increased risk of developing type 2 diabetes

• 48 mmol/mol or above: Indicative of type 2 diabetes — in asymptomatic adults, a second confirmatory test on a separate occasion is required; in adults with clear symptoms of diabetes, a single result may be sufficient

These ranges apply to adults without conditions that affect red blood cell turnover or haemoglobin structure. They do not apply to children and young people, pregnant women, or those with suspected type 1 diabetes, for whom different diagnostic pathways are used.

For people already diagnosed with diabetes, target HbA1c levels are individualised. NICE guideline NG28 recommends a target of 48 mmol/mol (6.5%) for most people with type 2 diabetes managed with lifestyle changes or a single non-hypoglycaemic drug. Targets may be adjusted — typically to 53 mmol/mol (7.0%) — for those on medications that carry a risk of hypoglycaemia, such as sulphonylureas or insulin. Targets may also be modified for people with frailty, significant comorbidities, or a limited life expectancy, in discussion with their healthcare team.

It is important to understand that HbA1c is an average — it does not capture day-to-day fluctuations in blood glucose, episodes of hypoglycaemia, or postprandial (after-meal) glucose spikes. A result within the target range does not necessarily mean blood glucose has been consistently stable throughout the period. For this reason, HbA1c is often used alongside other monitoring tools, such as self-monitored blood glucose readings or continuous glucose monitoring (CGM) where appropriate.

Red-flag advice: If you experience symptoms of hyperglycaemia — such as excessive thirst, frequent urination, unexplained weight loss, or blurred vision — do not wait for a routine HbA1c result. Contact your GP promptly. If you feel acutely unwell, particularly with nausea, vomiting, or rapid breathing, seek emergency care immediately, as these may be signs of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycaemic state (HHS).

Not sure if this is normal? Chat with one of our pharmacists →

If your result is higher than expected, your healthcare team will discuss it with you and consider whether any changes to your diet, lifestyle, or medication are needed. If you have concerns about a result, contact your GP surgery for clarification.

Medicines and side effects: If you are taking medicines that can cause hypoglycaemia (low blood sugar), such as insulin or a sulphonylurea, and you experience a suspected side effect, you can report this to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

Factors That Can Affect HbA1c Blood Test Accuracy

Haemolytic anaemia, haemoglobin variants, recent blood transfusion, iron deficiency, and chronic kidney disease can all cause spuriously high or low HbA1c results, necessitating clinical interpretation alongside glucose data.

While the HbA1c test is highly reliable, several physiological and clinical factors can influence its accuracy, potentially leading to spuriously high or spuriously low results. Healthcare professionals are trained to recognise these variables and interpret results accordingly.

Conditions that may affect HbA1c results include:

• Haemolytic anaemia — increased red blood cell turnover shortens red cell lifespan, reducing glycation time and typically lowering HbA1c

• Iron deficiency anaemia (untreated) — reduced red cell turnover prolongs glycation exposure and may raise HbA1c; during iron replacement therapy, results may be transiently unreliable as red cell populations change

• Vitamin B12 or folate deficiency — similarly affects red cell lifespan and may alter HbA1c

• Recent blood transfusion — introduces donor red blood cells not exposed to the patient's glucose levels; the direction of effect depends on the donor's HbA1c and the proportion of transfused cells, making results unreliable

• Haemoglobin variants (e.g., sickle cell trait, HbS, HbC, HbE) — some variants interfere with certain assay methods and can cause results to be spuriously high or low depending on the assay used

• Chronic kidney disease (CKD) — in advanced CKD, reduced red cell lifespan (due to haemolysis or erythropoietin deficiency) may lower HbA1c; older assay methods may also be affected by carbamylation of haemoglobin; the direction and magnitude of effect varies with disease severity and assay type

• Splenectomy — removal of the spleen prolongs red cell survival and may raise HbA1c

• Other factors — recent significant haemorrhage, erythropoietin (EPO) therapy, certain medicines (e.g., dapsone, some HIV antiretroviral treatments), and the postpartum period may also affect reliability

Because the direction and magnitude of these effects depend on the clinical context and the assay method used, results in affected patients should always be interpreted alongside clinical glucose data. In patients where HbA1c reliability is in doubt — particularly those with known haemoglobin variants — alternative methods of glycaemic assessment, such as fructosamine testing, self-monitored blood glucose (SMBG), or continuous glucose monitoring (CGM), may be more appropriate.

Laboratories in the UK select assay methods with reference to guidance from the Association for Clinical Biochemistry and Laboratory Medicine (ACB), the Royal College of Pathologists (RCPath), and UK NEQAS for HbA1c, which provides external quality assessment and commentary on haemoglobin variant interference.

If you have a known blood disorder, haemoglobin variant, are pregnant, have recently had a blood transfusion, or are receiving EPO therapy, inform your GP or phlebotomist before your test. This allows your clinician to interpret your result with appropriate caution and, if necessary, request supplementary investigations or use an alternative diagnostic approach.

Frequently Asked Questions